Clarithromycin for 2 weeks for stable coronary heart disease: 6-Year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

Cardiology

Volumn 111, Issue 4, 2008, Pages 280-287

  Gluud, Christian ^a,b   Als Nielsen, Bodil ^c   Damgaard, Morten ^d   Fischer Hansen, Jørgen ^d   Hansen, Stig ^e   Helø, Olav H ^a   Hildebrandt, Per ^f   Hilden, Jørgen ^g   Jensen, Gorm Boje ^e   Kastrup, Jens ^a   Kolmos, Hans Jørn ^h   Kjøller, Erik ⁱ   Lind, Inga ^j   Nielsen, Henrik ^c   Petersen, Lars ^f   Jespersen, Christian M ^a,d  

^a Mental Health Services CPH   (Denmark)

^b The Capital Region   (Denmark)

^c AMAGER HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f FREDERIKSBERG HOSPITAL   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^j STATENS SERUM INSTITUT   (Denmark)

more..

Author keywords

Antibiotics; Cardiovascular mortality; Chlamydia pneumoniae; Clarithromycin; Coronary heart disease; Macrolides

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; KLACID UNO; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CONFIDENCE INTERVALS; CORONARY DISEASE; DENMARK; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; ODDS RATIO; RISK; SURVIVAL ANALYSIS;

EID: 55249099789     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000128994     Document Type: Article

References (34)

1. Andraws R, Berger JS, Brown DL: Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005;293:2641-2647.
2. Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, HeløOH, et al: Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-27. DOI: 10.1136/bmj.38666.653600.55.
3. Berg HF, Maraha B, Scheffer G-J, Quarles van Ufford M, Vandenbroucke-Grauls CM, Peeters MF, Kluytmans JA: Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 2005;40:358-365.
4. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al: Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005;352:1646-1654.
5. Grayston JT, Kronmal R, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al: Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637-1645.
6. Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM, The CLARICOR Group: Intervention with clarithromycin in patients with stable coronary heart disease: the CLARICOR trial design. Heart Drug 2001;1:14-19.
7. Als-Nielsen B, Gluud C: Antibiotics for secondary prevention of coronary heart disease (protocol). Cochrane Database Syst Rev 2002;2:CD003610. DOI:10.1002/14651858.CD003610.
8. Review Manager (RevMan) (Computer Program). Version 4.2 for Windows. Copenhagen, The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
9. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
10. Neumann F-J, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, et al: Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001;357:2085-2089.
11. Parachure N, Zouridakis EG, Kaski JC: Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002;105:1298-1303.
12. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM: Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733-738.
13. Radoi M, Bobescu E, Agache I: Rovamycine as add-on treatment in unstable angina and 4 year evolution with major cardiovasular events. Rom J Intern Med 2003;41:237-246.
14. Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, et al: Effects of a brief course of azithromyzin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study. Am Heart J 2004;148:72-79.
15. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonene J, Melin J, et al: Effect of 3 months of antimicrobial treatment with clarithromycin in acute on Q wave coronary syndrome. Circulation 2002;105:1555-1560.
16. Fischer SF, Vier J, Kirschnek S, Klos A, Hess S, Ying S, et al: Chlamydia inhibits host cell apoptosis by degradation of proapoptotic BH3-only proteins. J Exp Med 2004;200:905-916.
17. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al: Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001;103:351-356.
18. Berg HF, Maraha B, Scheffer G-J, Peeters MF, Kluytmans JAJW: Effect of clarithromycin on inflammatory markers in patients with atherosclerosis. Clin Diagn Lab Immunol 2003;10:525-528.
19. Ohara T, Kanoh Y, Higuchi K, Arakawa T, Morisita T: Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa - possible mechanism for cure of peptic ulcer disease and MALT lymphoma with low-grade malignancy. Hepatogastroenterology 2003;50:607-609.
20. Mizunoe S, Kadota J, Tokimatsu I, Kishi K, Nagai H, Nasu M: Clarithromycin and azithromycin induce apoptosis of activated lymphocytes via down-regulation of Bcl-xL. Int Immunopharmacol 2004;4:1201-1207.
21. Ishimatsu Y, Kadota J, Iwashita T, Nagata T, Ishii H, Shikuwa C, et al: Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro. Int J Antimicrob Agents 2004;24:49-55.
22. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
23. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al: Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-613.
24. Kjærgard LL, Villumsen J, Gluud C: Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982-989.
25. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, et al: Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786. DOI: 10.1136/bmj.39136.682083.AE.
26. Martin D, Bursill J, Qui MR, Breit SN, Campbell T: Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet 1998;351:1858-1859.
27. Food and Drug Agency: FDA Alert for Healthcare Professionals: Clarithromycin (in the CLARICOR Study). http://www.fda.gov/cder/drug/InfoSheets/ HCP/clarithromycinHCP.pdf (accessed November 14, 2007).
28. The Danish Medicines Agency: Clarithromycin for patients with ischemic heart disease. December 8, 2005. http://www.dkma.dk/1024/visUKLSArtikel.asp? artikelID=7597 (accessed November 14, 2007).
29. Ioannidis JP: Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005;294:218-228.
30. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromyzin in male survivors of myocardial infarction. Circulation 1997;96:404-407.
31. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, ROXIS Study Group: Randomised trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-407.
32. Grayston JT: Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003;107:1228-1230.
33. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Mortality in randomized trials of antioxidant supplements for primary and secondary prevention. Systematic review and meta-analysis. JAMA 2007;297:842-857.
34. Libby P, Ridker PM: Inflammation and atherothrombosis. From population biology and bench research to clinical practice. J Am Coll Cardiol 2006;48(suppl 1):A33-A46.